EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases

Sponsor
Assistance Publique - Hôpitaux de Paris
Study ID
NCT07077304
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • observational study — OTHER
    observational study

Study Details

Inflammatory Cardiovascular Diseases and Autoimmune Rheumatic Diseases (ICARDs) encompass cardiovascular involvement in connective tissue diseases, vasculitis, and primary inflammatory cardiac processes affecting all layers of the heart. ICARDs are associated with increased cardiovascular morbidity and mortality, independently of traditional risk factors, via multiple pathophysiological mechanisms. Diagnosis and prognosis are challenged by the heterogeneity of clinical presentations. Multimodality cardiovascular imaging - including cardiovascular magnetic resonance (CMR), transthoracic echocardiography, and positron emission tomography (PET) - plays a central role in detecting and characterizing inflammatory involvement, and may offer prognostic insights. Given the limited data on the diagnostic and prognostic utility of these imaging modalities in ICARDs, the EACVI-INFLAME study aims to assess the prevalence of confirmed cardiovascular involvement in patients with suspected or established ICARDs undergoing CMR and/or cardiac PET in a multicentric international cohort.

Key Dates

Start date
Nov 19, 2025
Status verified
May 2026
Primary completion
Aug 31, 2027
Completion
Oct 30, 2028

Study Design

Enrollment
5,000 participants (estimated)

Primary Outcome Measure

Proportion of patients with confirmed cardiovascular involvement among consecutive patients with a suspicion of cardiovascular involvement due to a suspected or known ICARD referred for CMR and/or nuclear imaging exam. [ Time Frame: At each diagnostic assessment point, up to study completion, an average of 1 year. ]

Related Studies